Tag: ODAC Committee

1
ODAC Committee Votes to License Sandoz’s Zarxio®

ODAC Committee Votes to License Sandoz’s Zarxio®

Sandoz Inc. filed the first biosimilar application under the Biologics Price Competition and Innovation Act on July 24, 2014 for a biosimilar version of Amgen Inc.’s Neupogen® (filgrastim). The FDA issued a Briefing Document for the Oncologic Drugs Advisory Committee Meeting held January 7, 2015 concluding that Sandoz’s biosimilar, referred to as EP2006 in the FDA’s Briefing Document, is highly similar to and has no clinically meaningful differences from Neupogen®.

To read the full alert, click here.

Copyright © 2019, K&L Gates LLP. All Rights Reserved.